Abstract: Magnolol is a pharmacological biphenolic compound extracted from Chinese herb Magnolia officinalis, which displays anti-inflammatory and antioxidant effects. This study was aimed at exploring the potential effect of magnolol on immune-related liver fibrosis. Herein, BALB/c mice were injected with concanavalin A (ConA, 8 mg/kg/week) up to 6 weeks to establish hepatic fibrosis, and magnolol (10, 20, 30 mg/kg/day) was given to these mice orally throughout the whole experiment. We found that magnolol preserved liver function and attenuated liver fibrotic injury in vivo. In response to ConA stimulation, the CD4 + T cells preferred to polarizing towards CD4 + T helper 17 (Th17) cells in liver. Magnolol was observed to inhibit Th17 cell differentiation in ConA-treated liver in addition to suppressing interleukin (IL)-17A generation. Hepatic stellate cells were activated in fibrotic liver as demonstrated by increased alpha smooth muscle actin (a-SMA) and desmin. More transforming growth factor (TGF)-b1 and activin A were secreted into the serum. Magnolol suppressed this abnormal HSC activation. Furthermore, the phosphorylation of Smad3 in its linker area (Thr179, Ser 204/208/213) was inhibited by magnolol. In vitro, the recombinant IL-17A plus TGF-b1 or activin A induced activation of human LX2 HSCs and promoted their collagen production. Smad3/Smad4 signalling pathway was activated in LX2 cells exposed to the fibrotic stimuli, as illustrated by the up-regulated phospho-Smad3 and the enhanced interaction between Smad3 and Smad4. These alterations were suppressed by magnolol. Collectively, our study reveals a novel antifibrotic effect of magnolol on Th17 cell-mediated fibrosis.
Liver fibrosis is a dynamic process mainly featured by overproduction of extracellular matrix (ECM) [1] . Fibrogenesis has been recognized as a reversible scarring response in liver, but the continued fibrogenesis can cause organ dysfunction and subsequent organ failure [2] . In general, an imbalance that favours fibrogenesis over fibrolysis occurs during the development of liver fibrosis [3, 4] . Progress made in revealing the underlying mechanisms of fibrosis has given realistic hopes to patients with hepatic fibrosis, yet challenges still remain [5] .
Magnolol is a pharmacological biphenolic compound isolated from Magnolia officinalis, which has been reported to possess anti-inflammatory and antioxidant capability [6] . In vivo, magnolol is able to ameliorate bleomycin-induced pulmonary fibrosis [7] . In vitro, magnolol can inhibit the expression of transforming growth factor-b (TGF-b), a well-known fibrogenic cytokine, under high-glucose condition [8] . These earlier findings suggested an antifibrotic potential of magnolol. Interestingly, the administration of Magnolia officinalis by gavage is reported to attenuate alcoholic fatty liver injury in rats, indicating a hepatoprotective effect of this herb [9] . Notably, after repeated oral dosing to rodents, magnolol predominantly distributes in the liver and has no obvious toxicity [10] . We therefore propose that magnolol may mitigate hepatic fibrosis.
In fibrotic liver, about 90% contractile and fibrogenic myofibroblasts are yielded from activated hepatic stellate cells (HSCs) [11, 12] . Once activated, the HSCs contribute to fibrosis by interacting with other liver-resident cells such as hepatocytes and Kupffer cells, and with the infiltrated immune cells such as CD4 + T lymphocytes [13] . In the liver, polarized CD4 + T cells, T helper (Th)-1, (Th)-2 and (Th)-17, are major regulators for immune response during fibrosis development [14] . Interleukin (IL)-17 is a pro-inflammatory and fibrogenic cytokine that is mainly generated by Th17 cells [15] . As the major IL-17 cytokine, IL-17A is capable of initiating the downstream signalling by binding to its cognate receptors (IL17Rs) [16] . In various animal models for liver fibrosis, the enhanced infiltration of Th17 cells and the elevated expression of IL-17 can be observed [17, 18] . The activated IL-17 signalling is reported to accelerate liver fibrosis as demonstrated in IL-17RA-deficient mice [19] . Besides epithelial cells, fibroblasts, B and T lymphocytes, HSCs also express IL-17Rs [16, 20] , indicating HSCs as potential target cells of IL-17. As reviewed by Pellicoro et al. [21] , immune regulation plays a critical role in hepatic fibrosis and cirrhosis. Multiple injections of concanavalin A (ConA) can induce an immunerelated liver fibrosis [22] . To investigate whether magnolol could ameliorate immune-associated liver fibrosis, magnolol was given to mice with ConA-induced liver fibrosis in this study. Alleviative fibrotic injury was found in mouse liver Author for correspondence: Hongjun Zhang, Department of Immunology, Mudanjiang Medical University, 3 Tongxiang Street, Mudanjiang, Heilongjiang 157011, China (e-mail zhj1969_2@163.com).
after magnolol treatment, which was accompanied by weakened TGF-b/activin signalling. Moreover, magnolol also inhibited the Th17 differentiation in liver and suppressed IL-17A plus TGF-b/activin A-induced HSC activation in vitro.
Materials and Methods
Animal model. BALB/c mice (weighing 20-23 g, 8-10 weeks old) were obtained from Liaoning Changsheng Bio-tech Co., Ltd. (Benxi, China), maintained under a 12-hr light/dark cycle and allowed to access food and water freely. The animal experiments were approved by the Institutional Animal Care and Use committee of Mudanjiang Medical University.
For establishment of immune hepatic fibrosis animal model, the mice in ConA group were given intravenous (I.V.) injections of ConA (8 mg/ kg, Sigma-Aldrich, St. Louis, MO, USA) up to 6 weeks [23] . A total of 48 mice were randomly divided into six groups (n = 8/group): 1) control; 2) ConA; 3-5) ConA + 10, 20, 30 mg/kg magnolol; 6) Control + 30 mg/kg magnolol. Magnolol doses used in this study were chosen based on our pre-experiments and a previous study [7] . The mice in groups 3-6 were given daily magnolol (oral; Purity >98%; Aladdin, Shanghai, China) throughout the experimental period. At the end of the experiment, serum sample was obtained from each animal, and liver tissue was collected and stored properly after the mice were killed.
Cell culture. Human LX2 cells (ZhongqiaoBio, Shanghai, China) were cultured with DMEM (Gibco, Grand Island, NY, USA) containing 10% FBS (HyClone, Logan, UT, USA) in standard cell culture environment. Recombinant human IL-17A (Purity >97%), TGF-b1 (Purity >95%) or activin A (Purity >97%) were purchased from Sino Biological Inc. (Beijing, China) or PeproTech (Rocky Hill, NJ, USA). LX2 cells of 80% confluence were stimulated with IL-17A plus TGF-b1/activin A for 12, 24 and 48 hr in serum-free conditions. Moreover, cells were pre-treated with different doses of magnolol for 30 min. prior to the 1-hr or 48-hr stimulation of the fibrotic cytokines. The concentrations of IL-17A (1 ng/mL), TGF-b1 (0.5 ng/mL) and/or activin A (5 ng/mL), magnolol (1, 3 and 10 lM) used in this study were based on a previous study [24] 
Morphological analysis and immunofluorescence (IF).
Formaldehydefixed liver tissues were washed with water for 4 hr, dehydrated with gradient alcohols (70%, 80%, 90%, 100%) and embedded into paraffin. Then, the tissue block was cut into 5-lm-thick sections, slowly spread in water and dried at 60°C. Then, these slices were dewaxed in xylene (Sinopharm, Shanghai, China), rehydrated in gradient alcohols (95%, 85%, 75%) and soaked in water for 2 min. For haematoxylin and eosin (H&E) staining, the prepared tissue slices were stained with haematoxylin (Solarbio, Beijing, China) for 5 min. and with eosin (Sinopharm) for 3 min.
For detection of collagen deposition, these slices were stained with Sirus Red (Solarbio) for 1 hr and with haematoxylin (Solarbio) for 5 min.
For IF, these slices were boiled in antigen retrieval buffer for 10 min., cooled to room temperature (RT) and washed with PBS three times. Then, the slices were incubated with goat serum for 30 min. and then with a-SMA (1:200 dilution; Bioss), Desmin (1:50 dilution; Santa Cruz Biotechnology) and CD4 (1:200 dilution; Proteintech, Rocky Hill, NJ, USA) overnight at 4°C. Cyanine-3-CTP (Cy3)-labelled goat anti-rabbit (1: 200 dilution, Beyotime) or goat anti-mouse antibody (1: 200 dilution, Beyotime) was used to treat tissue slices at RT for 60 min. in the dark. Cell nuclei were stained with DAPI (Biosharp, Hefei, China). For the IF assay of a-SMA in vitro, cells grown on glass slides were fixed in 4% paraformaldehyde, washed with PBS and then incubated with 0.1% Triton X-100 for 30 min. at RT. The rest experiments were performed as the protocols described above. Liver samples (three random slices for one animal) from five individuals in each group were used for the CD4 + -positive cell counting.
Co-immunoprecipitation (co-IP) assay. Total protein samples were isolated from LX2 cells using RIPA buffer and quantified with a BCA Protein Assay Kit. Proteins in the cell lysates (400 lg) were immunoprecipitated with anti-Smad3 antibody (5 lg/mL, Abcam), followed by incubation with 40 lL ProteinA+G Agarose (Beyotime) at 4°C for 3 hr. The immunoprecipitates were washed, mixed with SDS-PAGE loading buffer and then incubated in boiling water bath for 5 min. Then, these samples were subjected to Western blot assay using a rabbit monoclonal for Smad4 (1:5000 dilution, Abcam).
Quantitative real-time PCR (qRT-PCR). Primers used for detecting the mRNA expression of IL-17A in mouse liver and a-SMA in human LX2 cells were designed as follows: IL-17A (Forward): 5
. Total RNAs were isolated via an RNApure Extraction kit (BioTeke, Winooski, VT, USA) and were processed as cDNAs by Super M-MLV reverse transcriptase (BioTeke). The relative mRNA expression level of a target gene was detected on the ExicyclerTM 96 real-time quantitative thermal block using SYBR GREEN mastermix (Solarbio) and was calculated via 2
ÀDDCt method against b-actin.
Identification of Th17 cells in liver. The portion of Th17 cells in CD4 + T cells was determined via flow cytometry with proper antibodies as described before [25] . Liver non-parenchymal cells were first isolated via Percoll centrifugation (Solarbio). Briefly, the liver was perfused with Hank's balanced salt solution for 5 min., then with 0.5 mg/mL pronase (Dalian Meilun Biotech Co., Ltd, Dalian, China) for 4 min., and then with 0.25 mg/mL collagenase (Invitrogen, Carlsbad, CA, USA) for 4 min. Then, these tissue samples were cut into 1-3 mm 3 cubes and further digested with collagenase/pronase/ DNase at 37°C for 20 min. Thereafter, the mix was filtered, centrifugation at 300 9 g for 10 min. (4°C). The cell pellets were collected and resuspended in 40% Percoll solution and were carefully placed on 70% Percoll solution and then centrifuged at 450 
Results

Magnolol attenuates immune-associated liver fibrosis in mice.
Mice received weekly injections of ConA and were given different doses of magnolol. We found that magnolol inhibited ConA-induced elevation of ALT and AST in the mice ( fig. 1A) . Apparent pathological changes, such as congestion of hepatic sinusoids and infiltration of inflammatory cells, were observed in the liver section of ConA-treated mice ( fig. 1B) . Obvious fibrosis presented in the ConA-treated liver as illustrated by Sirus Red staining ( fig. 1C) . Moreover, magnolol treatment mitigated the fibrosis and reduced the collagen and hydroxyproline in liver ( fig. 1C and D) . Additionally, we also tested whether high concentration of magnolol had any hepatotoxic effect in healthy mice. As shown in fig. 1A , serum ALT and AST levels in control mice treated with 30 mg/kg/day magnolol remained unchanged as compared to the untreated ones. H&E staining also showed a normal histological structure of hepatic lobule in these mice (fig. 1B) . As magnolol alone did not impact the liver function in normal mice, this group was omitted from the following molecular mechanism study. fig. 2A and C) . Less CD4 + cells were infiltrated into liver when mice were given a high dose of magnolol ( fig. 2A and C fig. 2B and D) . Interestingly, magnolol inhibited this conversion ( fig. 2B and D) . Furthermore, the serum and liver expression of IL-17A were increased in mice with fibrotic injury but decreased in those given magnolol ( fig. 2E and F) . Our results indicated that the administration of magnolol had an inhibitory effect on ConAinduced Th 17 cell differentiation in mouse liver.
Magnolol suppresses ConA-induced HSC activation in liver in vivo. We further tested whether magnolol impacted HSC activation in vivo. The activated HSCs in mouse liver were marked with a-SMA or desmin via IF assay. Apparent activation of HSCs in the liver of mice with immune-related fibrosis was observed ( fig. 3A and B) . However, this abnormal activation of HSCs was suppressed by 20 and 30 mg/ kg/day magnolol, however not completely ( fig. 3A and B) . The protein expression of molecules in fibrotic TGF-b/activinA/Smad3 signalling pathway was determined with ELISA or Western blot analysis. We noted that more TGF-b1 and activin A were secreted into blood in mice treated with chronic ConA (fig. 3C) . Furthermore, the expression of TGF-bRII, ACVR2A and the phosphorylated Smad3 was increased by ConA stimulation, whereas decreased by magnolol ( fig. 3D ). Collectively, magnolol inhibited HSC activation in fibrotic liver tissue.
Magnolol inhibits the activation of LX2 cells and partly blocks Smad 3/4 signalling in vitro.
We next studied the effect of magnolol on HSC activation in vitro. Human LX2 HSCs were stimulated with recombinant IL-17A plus TGF-b1/activin A. The mRNA and protein expression of a-SMA was detected with qRT-PCR, Western blot and IF assay. A weak expression of a-SMA was found in untreated LX2 cells, whereas a strong expression was found in cells treated with IL-17A and TGF-b1/activin A ( fig. 4A and  B) . In response to pro-fibrotic stimuli, cells treated with magnolol exhibited a weaker expression of a-SMA as compared to the untreated cells and produced less collagen ( fig. 4C and  D) . Moreover, in order to clarify the contribution of Th17 cells to HSC activation, LX2 cells were treated with recombinant TGF-b1 or activin A in the presence or absence of IL17A. We found that the stimulation with TGF-b1 or activin A alone also induced increases in a-SMA and collagen I in LX2 cells. However, the extent was less significant than cells treated with TGF-b1/activin A in the presence of IL17A (Figure S1 ), suggesting a contributory role of IL-17 in HSC activation. Treatment of high-dose magnolol was also able to reduce the single stimulation of TGF-b1 or activin A-induced HSC activation ( Figure S1 ).
Additionally, the pro-fibrotic cytokines-induced activation of Smad3 pathway was also partly blocked by magnolol as demonstrated by decreased phosphorylated Smad3 (fig. 5A ). The interaction between Smad3 and co-Smad (Smad4) was disrupted by magnolol ( fig. 5B ). These results indicated that magnolol inactivated LX2 cells at least partly through inhibiting Smad3/Smad4 signalling transduction. 
Discussion
Liver is a central immunological organ that is exposed to circulating antigens and endotoxins from gut microbiota and is particularly enriched for immune cells, such as lymphocytes and macrophages [26] . Repeated ConA challenge resembles the fibrosis progression of human viral and autoimmune hepatitis and thus is considered as a proper animal model to study immune-associated liver fibrosis [22] . In this study, apparent fibrotic injury and aberrant AST and ALT activities were observed in mice that received a 6-week administration of ConA. Such pathological changes were alleviated by magnolol in a dose-dependent manner. The activation of HSCs and the polarization of CD4 + T towards Th17 cells were inhibited by magnolol in vivo. In vitro, collagen over-produced by the activated LX2 cells was suppressed by magnolol as well. Moreover, the Smad 3/4 signalling delivery was partly blocked by magnolol. These results suggested a novel antifibrotic effect of magnolol in liver fibrosis. As an isomer of magnolol, honokiol is found to attenuate the acute and chronic liver injury induced by carbon tetrachloride (CCL 4 ) [27] . Although magnolol itself shows the capacity to ameliorate bleomycin-induced fibrosis in lung [7] , whether such antifibrotic effect is also valid in liver remains unknown. To our best knowledge, the present study is the first to show the therapeutic effect of magnolol in T-cell-mediated liver fibrosis. CD4 + T helper cells have been identified as an essential driver for diverse liver diseases, rendering them an attractive cellular target. Viral infection-induced loss of CD4 + T cells together with impaired activity of CD4 + T cells may accelerate the progression of liver fibrosis [28] . Upon different polarizing cues, Naive T cells develop into Th subsets with distinct effector functions and different cytokine profiles [29] . As a novel subset of T helper cells, Th17 cells are reported to accumulate in liver and secrete specific pro-fibrotic IL-17s, contributing to fibrosis development [30] . In ConA-induced liver fibrosis, we and others [18, 31] observed that the Th17 (CD4 + / IL17A + ) cells were abnormally accumulated in liver. Interestingly, these pathological changes were attenuated by magnolol, and for all we know, our results revealed a novel phenomenon that magnolol could inhibit Th17 cell polarization and IL-17 production. Nonetheless, a limitation of our current work was that we only focused on Th17 differentiation. Notably, besides Th17, other polarized CD4 + T cells, such as Th1 and Th2 are also major regulators of immune response in fibrosis progression [14] . Reportedly, deceleration of Th1/Th2 balance towards a Th2-dominant response can attenuate fibrosis occurring in multiple organs, such as in lung [32] and in heart [33] . Further study is required to investigate whether magnolol exhibits its therapeutic effect by regulating Th1/Th2 balance. TGF-bs and activins are two major TGF-b-like subgroups of the TGF-b superfamily [34] . Their aberrant elevation is considered as a causal factor for fibrotic injury in lung [35] , kidney [36] and heart [37] . Like TGF-bs, activins are homodimers and heterodimers consisting of different activin subunits [38]. Signals for TGF-b family are delivered through heteromeric complexes comprised of type I and II ser/thr kinase receptors [39, 40] . It has been reported that the autocrine factor TGF-b stimulates TGF-bRII expression [41] and that TGF-b and activin A stimulate each other's expression in HSCs, promoting collagen production [42] . Corresponding to earlier studies revealing an enhanced activation of TGF-b signalling [43] , we also found much higher expression of TGF-b1 and activin A and their receptors TGF-bRII and ACVR2A in ConA-treated liver. Magnolol inhibited such elevation. This inhibitory effect of magnolol had been demonstrated in retinal pigment epithelial cells and muscle cells [8, 44] but not in HSCs. In fact, our present work revealed a novel inhibitory effect of magnolol on the activated HSCs.
Smad proteins are critical intracellular mediators of the TGF-b signalling transduction pathway, which consists of two Mad homology domains (MH1 and MH2) connected by a linker region [45] . As a consequence of activation, heteromeric complexes formed of TGF-b ligands and their receptors recruit and phosphorylate the receptor-regulated Smads (R-Smads), which in turn translocate in cell nucleus and mediate gene expression [34, 38] . Smad3 is a R-Smad which plays an important role during fibrotic progress, as demonstrated by the reduced fibrogenesis in Smad3-null mice [46] . Because magnolol inhibited TGF-b1/activin A expression in fibrotic liver, we suggested that magnolol could inhibit Smad signalling. As expected, the ConA-induced increase in phospho-Smad3 was suppressed by magnolol.
It is increasingly clear that the phosphorylation occurred in the linker region of Smad3 is critical for its activity [45] . TGF-b1 and pro-inflammatory cytokines cooperatively promote the synthesis of collagen by enhancing the phosphorylation of Smad3 at linker Thr-179 in HSCs [47] . However, in sharp contrast, Smad3-null mouse embryonic fibroblasts that express Smad3-mutant (at Thr-179) generate more collagen in response to TGF-b stimulation [48] . These two lines of evidence suggest that the activated pSmad3L (Thr-179) signalling may be pro-fibrotic in HSCs, yet not in fibroblasts. Besides Thr-179, Smad3 linker region also contains other three demonstrated phosphorylation sites, Ser-204, Ser-208 and Ser-213, which are linked to pro-fibrotic signalling [49, 50] . During fibrosis, many different types of cells are presented in liver [13] . As the collagen production mediated by the linker region of Smad3 may have a cell phenotype-specific manner, testing the direct effect of magnolol on the main ECM-generating cell type, HSCs, is needed. Based on a previous study revealing IL-17A and TGF-b, co-treatment can effectively stimulate the activation of LX2 human HSCs [24] ; in this study, we used the recombinant IL-17A plus two important TGF-b family members, TGF-b1 or activin A to treat LX2 cells. The expression levels of a-SMA and COL1A1 were markedly up-regulated in response to IL-17A/TGF-b stimulation, and these increases were inhibited by magnolol. Moreover, the enhanced linker phosphorylation of Smad3 at the above said four sites in activated HSCs was suppressed by magnolol. The phosphorylated Smad3 forms heterotrimers with Smad4 and translocates into the nucleus to regulate its targets [45] . Therefore, we also analysed whether Smad3-Smad4 interaction was affected by magnolol. Interestingly, we found that the profibrotic factor-induced Smad3/Smad4 signal delivery in LX2 cells was partly impaired by magnolol. These in vitro findings along with the in vivo results revealed a novel antifibrotic potential of magnolol in liver fibrosis.
Of note, besides the stimulatory effect of TGF-b/activin A and their receptors, other kinases are also reported to contribute to the linker phosphorylation of Smad3 and Smad3/ Smad4 signalling delivery. These kinases include ERK MAP kinases, c-Jun N-terminal kinases, p38 MAP kinases and glycogen synthase kinase 3 [50, 51] . Exploring whether magnolol exhibits its suppressive effects on Smad 3 signalling transduction by impacting these kinases, though beyond the scope of our current work, will provide interesting insights into the molecular mechanisms underlying magnolol's hepatoprotective role. In addition, activation of Smad2 and Smad3 via phosphorylation at C-terminal tail is also important profibrotic signalling [47] . Thus, further experiments are being performed in our laboratory to investigate whether Magnolol affects the C-terminal phosphorylation of Smad2/Smad3.
In summary, our study reveals a novel antifibrotic role of magnolol in T-cell-mediated liver fibrosis in mice. Such protective effect may be associated with its inhibitory effect on Th17 cell-mediated Smad 3/4 signalling transduction in HSCs.
